BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Fox RK, Chu JN, Goldman ML, Islam KB, Brandman D. Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. Hepatol Commun 2023;7:e0024. [PMID: 36724121 DOI: 10.1097/HC9.0000000000000024] [Reference Citation Analysis]
2 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
3 Low ZS, Chua D, Cheng HS, Tee R, Tan WR, Ball C, Sahib NBE, Ng SS, Qu J, Liu Y, Hong H, Cai C, Rao NCL, Wee A, Muthiah MD, Bichler Z, Mickelson B, Lee JQ, Kong MS, Tay VS, Yan Z, Chen J, Ng AS, Yip YS, Vos MIG, Lim DXE, Chittezhath M, Yaligar J, Verma SK, Poptani H, Guan XL, Velan SS, Ali Y, Li L, Tan NS, Wahli W. Angiopoietin-like 4 shapes the intrahepatic T-cell landscape via eIF2α signaling during steatohepatitis in diet-induced NAFLD.. [DOI: 10.1101/2023.01.10.523354] [Reference Citation Analysis]
4 Aljobaily N, Krutsinger K, Viereckl MJ, Joly R, Menlove B, Cone B, Suppes A, Han Y. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. Nutrients 2022;15. [PMID: 36615835 DOI: 10.3390/nu15010178] [Reference Citation Analysis]
5 Valenzuela-Vallejo L, Guatibonza-García V, Mantzoros CS. Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation? Metabolism 2022;136:155248. [PMID: 35803320 DOI: 10.1016/j.metabol.2022.155248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
6 Porayko MK, Articolo A, Cerenzia W, Coleman B, Patel D, Stacy S. Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care. J Multidiscip Healthc 2022;15:1533-45. [PMID: 35898947 DOI: 10.2147/JMDH.S367607] [Reference Citation Analysis]
7 Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension 2022;79:1319-26. [PMID: 35465684 DOI: 10.1161/HYPERTENSIONAHA.122.17982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
8 Kouvari M, Sergi D, D’cunha N, Bulman A, Panagiotakos D, Naumovski N. Is Non-Alcoholic Fatty Liver Disease Connected with Cognition? The Complex Interplay between Liver and Brain. Diabetology 2022;3:355-363. [DOI: 10.3390/diabetology3020026] [Reference Citation Analysis]
9 Passos E, Pereira C, Gonçalves IO, Faria A, Ascensão A, Monteiro R, Magalhães J, Martins MJ. Physical exercise positively modulates nonalcoholic steatohepatitis-related hepatic endoplasmic reticulum stress. J Cell Biochem 2022. [PMID: 35467032 DOI: 10.1002/jcb.30250] [Reference Citation Analysis]
10 Villavicencio EA, Crocker RM, Garcia DO. A Qualitative Analysis of Mexican-Origin Men's Knowledge and Cultural Attitudes Toward Non-Alcoholic Fatty Liver Disease and Interest in Risk Reduction. Am J Mens Health 2021;15:15579883211063335. [PMID: 34872379 DOI: 10.1177/15579883211063335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Alexopoulos AS, Duffy R, Kobe EA, German J, Moylan CA, Soliman D, Jeffreys AS, Coffman CJ, Crowley MJ. Underrecognition of Nonalcoholic Fatty Liver Disease in Poorly Controlled Diabetes: A Call to Action in Diabetes Care. J Endocr Soc 2021;5:bvab155. [PMID: 34755002 DOI: 10.1210/jendso/bvab155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism 2021;122:154781. [PMID: 33901501 DOI: 10.1016/j.metabol.2021.154781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]